Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Uber Technologies Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Uber Technologies Inc trades at $69.16 (market cap $145.68B). The key difference: Uber Technologies Inc is far larger — about 16.4× Kymera Therapeutics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Uber Technologies Inc for 88 Days on average.
| KYMR | UBER | |
|---|---|---|
Market Cap | $8.87B | $145.68B |
Volume | 779,107 | 12,849,263 |
Sector | Health | Technology |
52-Week High | $127.31 | $99.72 |
52-Week Low | $55.80 | $65.94 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $8.26B | $155.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Uber (UBER) trades at $71.5, showing minimal daily change. The stock exhibits a bullish technical signal overall, with strong fundamentals including a 19.3% net income margin and robust revenue growth to $52.0B in 2025. Recent news highlights expansion of the Uber Eats partnership with Costco to 47 states, enhancing delivery reach. Cash flow from operations remains strong at $10.1B, though 2026 projections indicate a net cash outflow. Analyst sentiment is overwhelmingly positive with an 82.5% buy rating and a consensus price target of $104.72.
The outlook for Uber is favorable, driven by strategic expansions and solid financial performance. Investment opportunities include market share gains in mobility and delivery, supported by high institutional confidence. Key risks involve competitive pressures in autonomous vehicles, execution of growth initiatives, and potential macroeconomic headwinds affecting consumer spending. The stock's current valuation metrics, such as a P/E of 15.6, suggest room for appreciation relative to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
